Cisplatin + RT
Indication
Bladder cancer
Concurrent chemoradiation for stage II, III and non-metastatic stage IV cancer
- Cisplatin 100 mg/m2 iv d1 and 22
- Concurrent radiotherapy to 39.6 Gy
- Followed by consolidation
- Cisplatin 100 mg/m2 iv d1
- Radiotherapy to 25.2 Gy
References
Shipley, WU et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998; 16:3576
Cervical cancer
Concurrent chemoradiation
- Cisplatin 40 mg/m2 iv qw
- Concurrent radiotherapy 55-75 Gy
References
Rose PG et al. Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007; 25:2804
Rose PG et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Eng J Med 1999; 340:1144
Keys HM et al. Cisplatin, radiation and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Eng J Med 1999; 340:1154
